AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-29. (canceled)

30. (withdrawn, currently amended) A process for the preparation of a compound of formula (I)



(I)

in which:

- n represents an integer from 1 to 6;
- m represents an integer equal to 5, 6 or 7;
- R^1 represents either an OH group or an $-S-CH_2-(CH_2)_n-Z$ group, the R^1 groups all being identical;
- Z represents either:

* an NHX group,

* a quaternary ammonium group of the $^+NX_3$ form,

* a  group,

X representing a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms~~, and in particular being a methyl, ethyl, propyl or butyl group~~, and

R representing a hydrogen atom, a linear or branched alkyl substituent with 1 to 12 carbon atoms, or an aromatic group ~~such as the phenyl, benzyl or naphthyl group~~, or ~~derivatives of these groups~~ a derivative of said aromatic group carrying ~~substituents~~ at least one substituent on the aromatic ring ~~such as~~ selected from the group consisting of methyl, ethyl, chlorine, bromine, iodine, nitro, hydroxyl, methoxyl [[or]] and acetamido ~~substituents~~,

or R representing a biorecognition element ~~such as~~ comprising an amino acid derivative, a peptide, a monosaccharide, an oligosaccharide, a multiplication element with several branchings comprising glucidic groups which can be identical or different, or a visualization probe or fluorescent or radioactive detection probe,

said process ~~being characterized in that it comprises~~ comprising the following stages:

- ~~the reaction of~~ reacting a compound selectively or totally halogenated in primary alcohol position, of the following formula (VII):



(VII)

m being as defined above,

W representing an OH group or a Y group, the W groups all being identical,

and Y representing a halogen atom chosen from the group ~~constituted by~~ consisting of chlorine, bromine, and iodine, ~~and preferably being bromine or iodine,~~

with an ω-aminoalkanethiol of the following formula (VIII):



(VIII)

said ω-aminoalkanethiol optionally being N-alkylated,

or the corresponding salt of the following formula (VIII-a):



(VIII-a)

or a tetraalkylammonium salt of the following formula (VIII-b):



(VIII-b)

said salt being associated with a halide counter ion~~,~~ ~~preferably the chloride ion,~~

n and X being as defined above, ~~and X preferably being a hydrogen atom,~~

~~the compound of formula (VIII) preferably being cysteamine of formula $H_2N-CH_2-CH_2-SH$,~~

in order to obtain a compound of formula (I) as defined above and having the following formulae (A-a) or (A-b):



(A-a)



(A-b)

and ~~optionally~~

- the reaction of the compound of formula (A-a) as obtained in the preceding stage with an isothiocyanate of the following formula (IX):

(**IX**)

in which R is as defined above,

in order to obtain a compound of formula (I) as defined above, and corresponding to the following formula:



(**B**)

31. (withdrawn, currently amended) The preparation process according to claim 30 of a compound having the following general formula (I-b):



(**I-b**)

said process ~~being characterized in that it comprises~~ comprising the following stages:

- ~~the reaction of~~ reacting a per(6-deoxy-6-halo) cyclodextrin compound, of the following formula (VII-a):



(VII-a)

with an ω-aminoalkanethiol of the following formula (VIII):



(VIII)

said ω-aminoalkanethiol ~~optionally~~ being N-alkylated, or the corresponding salt of the following formula (VIII-a):



(VIII-a)

or a tetraalkylammonium salt of the following formula (VIII-b):



(VIII-b)

said salt being associated with a halide counter ion~~, preferably the chloride ion,~~

and X ~~preferably~~ being a hydrogen atom,

the compound of formula (VIII) ~~preferably~~ being cysteamine of formula $H_2N-CH_2-CH_2-SH$,

in order to obtain a compound of the following formulae (I-c), (I-d) or (I-e)



(I-c)



(I-d)



(I-e)

and ~~optionally~~

- the reaction of the compound of formula (I-c) as obtained in the preceding stage with an isothiocyanate of the following formula (IX):

(IX)

in order to obtain a compound of the following formula (II) or (II-a)



(II)



(II-a)

32. (withdrawn, currently amended) The preparation process according to claim 30 of compounds having the following formula:



(I-a)

said process ~~being characterized in that it comprises~~ comprising the following stages:

- ~~the reaction of~~ reacting a compound selectively halogenated in primary alcohol position, of the following formula (VII):



(VII)

with an ω-aminoalkanethiol of the following formula (VIII):



(VIII)

said ω-aminoalkanethiol optionally being N-alkylated,

or the corresponding salt of the following formula (VIII-a):



(VIII-a)

or a tetraalkylammonium salt of the following formula (VIII-b):



(VIII-b)

said salt being associated with halide as a counter ion, and preferably being the chloride ion,

and X ~~preferably~~ being a hydrogen atom,

the compound of formula (VIII) ~~preferably~~ being cysteamine of formula $H_2N-CH_2-CH_2-SH$,

in order to obtain a compound of formula (I-f) or (I-g), of the following formula:



(I-f)



(I-g)

and ~~optionally~~

- ~~the reaction of~~ reacting the compound of formula (I-f) as obtained in the preceding stage with an isothiocyanate of the following formula (IX):

(**IX**)

in order to obtain a compound of formula (I-h):

(**I-h**)

33. (withdrawn, currently amended) A process for the preparation of a compound of formula (I-f-bis)



(**I-f-bis**)

in which m and n are as defined in claim 30, ~~it preferably being~~ or n is equal to 1,

said process ~~being characterized in that it comprises the reaction of~~ comprising reacting a compound selectively

halogenated in primary alcohol position, of the following formula (VII):



(**VII**)

m being as defined above, and

Y representing a halogen atom chosen from the group ~~constituted by~~ consisting of chlorine, bromine, and iodine, ~~and preferably being bromine or iodine,~~

with an ω-aminoalkanethiol of the following formula:



n being as defined above,

or ~~preferably~~ with cysteamine of formula $H_2N-CH_2-CH_2-SH$.

34. (currently amended) A compound of the following general formula:



(**I**)

in which:

- n represents an integer from 1 to 6;

- m represents an integer equal to 5, 6 or 7;

- R^1 represents either an OH group or an $-S-CH_2-(CH_2)_n-Z$ group, the R^1 groups all being identical;

- Z represents either:

* an NHX group,

* a quaternary ammonium group of the $^+NX_3$ form,

* a  group,

X representing a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms, ~~and being in particular a methyl, ethyl, propyl or butyl group,~~ and

R representing a hydrogen atom, a linear or branched alkyl substituent with 1 to 12 carbon atoms, or an aromatic group ~~such as the phenyl, benzyl or naphthyl group~~, or ~~derivatives of these groups~~ a derivative of said aromatic group carrying ~~substituents~~ at least one substituent on the aromatic ring ~~such as~~ selected from the group consisting of methyl, ethyl, chlorine, bromine, iodine, nitro, hydroxyl, methoxyl [[or]] and acetamido ~~substituents~~,

or R representing a biorecognition element ~~such as~~ comprising an amino acid derivative, a peptide, a monosaccharide, an oligosaccharide, a multiplication element with several branchings comprising glucidic groups which can be identical or

different, or a visualization probe or fluorescent or radioactive detection probe,

provided that the compound in which n = 1, m = 6, Z = NH_2 and R_1 = OH is excluded.

35. (currently amended) The compound of claim 34, ~~characterized in that~~ wherein R^1 represents OH, and having the following general formula:



(I-a)

36. (withdrawn, currently amended) The compound of claim 34, ~~characterized in that~~ wherein R^1 represents OH, having the formula (I-a) and ~~characterized in that~~ wherein Z represents an NHX group, X ~~being as defined in claim 5, and in particular~~ being a hydrogen atom.

37. (currently amended) The compound of claim 34, ~~characterized in that~~ wherein R^1 represents OH, having the formula (I-a) ~~and characterized in that~~



(Ia)

---

and Z represents a



group, ~~R being~~ X being a hydrogen atom.

38. (currently amended) The compound of claim 34, ~~characterized in that~~ wherein R^1 represents an $-S-CH_2-(CH_2)_n-Z$ group, and having the following general formula:



(I-b)

39. (withdrawn, currently amended) The compound of claim 34, ~~characterized in that~~ wherein R^1 represents an $-S-CH_2-(CH_2)_n-Z$ group, and having the following formula:



(I-c)

.

40. (withdrawn, currently amended) The compound of claim 39, ~~characterized in that~~ wherein X represents a hydrogen atom and in that n is equal to 1, and having the following formula:



(I-d)

.

41. (withdrawn, currently amended) The compound of claim 38, corresponding to the following formula:



(I-e)

.

42. (currently amended) The compound of claim 38, ~~characterized in that~~ wherein Z represents a  group, and having the following formula:



(II)

R being identical for each  group.

43. (currently amended) The compound of claim 38, ~~characterized in that~~ wherein Z represents a  group, X represents a hydrogen atom and ~~in that~~ n is equal to 1, and having the following formula:



(II-a)

44. (currently amended) The compound of claim 34, ~~characterized in that~~ wherein at least one of the NHX groups as defined in formula (I) is protonated and associated with a monovalent anion chosen ~~in particular~~ from [[the]] chloride, bromide or iodide [[ion]].

45. (withdrawn, currently amended) The compound of claim 38, ~~characterized in that~~ wherein n is equal to 1 and ~~in that~~ the Z group represents the quaternary ammonium $^{+}NX_3$ group, and in that [[it]] the Z group can be associated with a monovalent anion chosen ~~in particular~~ from [[the]] chloride, bromide or iodide [[ion]], and having the following formula:



(I-e-bis)

46. (withdrawn, currently amended) The compound according to claim 34, ~~characterized in that~~ wherein R^1 represents an -S-CH_2-$(CH_2)_n$-Z group, ~~wherein~~ Z represents a 

group, X represents a hydrogen atom, n is equal to 1, and the R group is chosen from the following groups:

- the α-D-mannopyranosyl group, of the following formula (III):



(III)

- the β-lactosyl group, of the following formula (III-a):



(III-a)

- the group derived from Lewis X trisaccharide or from sialyl Lewis X tetrasaccharide, of the following formulae (III-b) and (III-c) respectively:



(III-b)



(III-c)

- an oligosaccharide derived from heparin, of the following formula (III-d):



(III-d)

47. (currently amended) The compound of claim 34, ~~characterized in that~~ wherein R^1 represents an $-S-CH_2-(CH_2)_n-Z$ group, ~~wherein~~ Z represents a  group, X represents a hydrogen atom, n is equal to 1, and:

R comprises a branching element ~~derived from~~ comprising tris(2-hydroxymethyl)methylamine, or

R represents one of the following groups:

- the tris(α-D-mannopyranosyloxymethyl)methyl group, of the following formula (IV):



(IV)

-the tris(β-lactosyloxymethyl)methyl group, of the following formula (IV-a):



(**IV-a**)

48. (currently amended) The compound of claim 34, wherein Z represents a  group, ~~characterized in that~~ wherein R comprises a branching element derived from pentaerythritol, said compound having the following formula:



(**V**)

in which R^2 and R^3 represent glucidic derivatives which can be different or identical or also a fluorescent or radioactive probe.

49. (currently amended) The compound of claim 48, ~~characterized in that~~ wherein R^1 represents OH.

50. (currently amended) The compound of claim 48, ~~characterized in that~~ wherein R^1 represents ~~the group of~~ formula:



51. (withdrawn, currently amended) The compound of claim 48, ~~characterized in that~~ wherein n is equal to 1, ~~in that~~ X represents a hydrogen atom and ~~in that~~ R^2 and R^3 represent one of the following groups:

- the α-D-mannopyranosyl group, of the following formula (III):



(III)

– the β-lactosyl group, of the following formula (III-a):



(III-a)

– the β-D-glucopyranosyl group, of the following formula (VI):



(VI)

R^2 and R^3 being able to be identical or different.

52. (currently amended) The compound of claim 34, ~~characterized in that~~ wherein m is equal to 6.

53. (currently amended) An inclusion complex of a compound according to claim 34 with a pharmacologically active molecule, [[the]] a molar ratio between the compound ~~according to claim 5~~ and the pharmacologically active molecule ~~advantageously~~ being approximately 50:1 to approximately 1:1.

54. (currently amended) An inclusion complex of a compound according to claim 34 with a pharmacologically active molecule, [[the]] a molar ratio between the compound ~~according to~~

~~claim 5 and~~ the pharmacologically active molecule ~~advantageously~~ being approximately 50:1 to approximately 1:1, ~~said complex being characterized in that~~ wherein the pharmacologically active molecule is an antineoplastic agent~~, in particular~~ belonging to the taxol family.

55. (previously presented) A pharmaceutical composition comprising a compound according to claim 34 with a pharmacologically acceptable vehicle.

56. (currently amended) A pharmaceutical composition comprising an inclusion complex of a compound according to claim 34, with a pharmacologically active molecule, [[the]] a molar ratio between the compound and the pharmacologically active molecule ~~advantageously~~ being approximately 50:1 to approximately 1:1, in association with a pharmacologically acceptable vehicle.

57. (previously presented) A pharmaceutical composition comprising a compound according to claim 34 with a pharmacologically acceptable vehicle, in the form of an aqueous solution.

58. (currently amended) A pharmaceutical composition comprising an inclusion complex of a compound according to claim 34 with a pharmacologically active molecule, [[the]] a molar

ratio between the compound and the pharmacologically active molecule ~~advantageously~~ being approximately 50:1 to approximately 1:1, in association with a pharmacologically acceptable vehicle, the pharmacological compound being in the form of an aqueous solution.

59. (currently amended) A pharmaceutical composition comprising a compound according to claim 34 with a pharmacologically acceptable vehicle, ~~characterized in that it~~ wherein the composition contains per single dose approximately 50 mg to approximately 500 mg of one of the ~~compounds~~ compound.

60. (currently amended) A pharmaceutical composition comprising an inclusion complex of a compound according to claim 34 with a pharmacologically active molecule, [[the]] a molar ratio between the compound and the pharmacologically active molecule ~~advantageously~~ being approximately 50:1 to approximately 1:1, in association with a pharmacologically acceptable vehicle, ~~characterized in that it~~ wherein the composition contains per single dose approximately 100 mg to approximately 750 mg of one of said complex.